Entries |
Document | Title | Date |
20090018190 | Compositions and Methods for Transdermal Oxybutynin Therapy - The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel. | 01-15-2009 |
20090036526 | CRYSTAL OF HYDROXYNOREPHEDRIN DERIVATIVE HYDROCHLORIDE 1/4 HYDRATE - The present invention provides ethyl (−)-2-[4-[2-[[1S,2R]-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-2,5-dimethylphenoxyacetate hydrochloride ¼ hydrate or a crystal thereof which can be determined by characteristic diffraction peaks of the powder X-ray diffraction, thermogravimetry-differential thermal analysis or the like, and obtained by manufacturing ethyl (−)-2-[4-[2-[[1S,2R]-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-2,5-dimethylphenoxyacetate by a specific method. | 02-05-2009 |
20090036527 | Therapeutic Application Of Leonurine In Treating Cardiomyopathy - The present invention provides methods for treating ischemic cardiomyopathy. In one embodiment, provided is a method of treating a disease characterized as ischemic cardiomyopathy, comprising administering to a subject suffering from said disease a pharmaceutical composition comprising therapeutically effective amount of synthesized Leonurine. The method induces at least one biochemical change to improve hypoxia myocardial cells survive rate, reduce LDH releasing from the ischemic myocardial cells, and reduce infarction area of cardiomyopathy in the subject. | 02-05-2009 |
20090076144 | DEUTERIUM-ENRICHED BAZEDOXIFENE - The present application describes deuterium-enriched bazedoxifene, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090124690 | Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins - The present invention relates to, in part, novel sulfate and bisphenol compounds useful for the recognition, attachment and growth of unwanted biologics on natural and manmade surfaces. Another aspect of the invention relates to combinatorial libraries for producing the same. Another aspect of the invention relates to pharmaceutical formulations comprising the same. | 05-14-2009 |
20090149534 | Crystalline modifications of (1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol - Crystalline modifications of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol, pharmaceutical compositions which contain these modifications, and the use thereof to treat pain or other conditions. | 06-11-2009 |
20090156671 | DEUTERIUM-ENRICHED OXYBUTYNIN - The present application describes deuterium-enriched oxybutynin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 06-18-2009 |
20090163588 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS - This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds. | 06-25-2009 |
20090247628 | SUBSTITUTED PHENYLCYCLOHEXYLGLYCOLATES - Disclosed herein are substituted phenylcyclohexylglycolate-based muscarinic acetylcholine receptor modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof. | 10-01-2009 |
20090264525 | FLUOROSURFACTANTS - The present invention relates to fatty acid esters of polyols or sulfonated fatty acid esters or sulfonated fatty acid amides containing at least one group Y, where Y stands for CF | 10-22-2009 |
20100010084 | HIGH PENETRATION PRODRUG COMPOSITIONS OF RETINOIDS AND RETINOID-RELATED COMPOUNDS - The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of retinoids and retinoid-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate. | 01-14-2010 |
20100093854 | PROCESS FOR THE PREPARATION OF (-)-(4-CHLORO-PHENYL)-(3-TRIFLUOROMETHYL-PHENOXY)-ACETIC ACID 2-ACETYLAMINO-ETHYL ESTER - The present invention is directed to a novel process for the preparation of (4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid 2-acetylamino-ethyl ester, useful in the treatment of metabolic disorders and further to a process for the preparation of (4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid, a synthesis intermediate. | 04-15-2010 |
20100093855 | USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDEMIA AND HYPERURICEMIA - The present invention provides the use of (−)(3-trihalomethylphenoxy)(4-halophenyl)acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia. | 04-15-2010 |
20100168232 | Oligomer-Anticholinergic Agent Conjugates - The invention provides anticholinergic agents that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different as compared to the characteristics of the anticholinergic agent not attached to the water-soluble oligomer. | 07-01-2010 |
20100216880 | TRANSDERMAL COMPOSITIONS FOR ANTICHOLINERGIC AGENTS - The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anticholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. A method is disclosed for treating a subject for urinary incontinence with these formulations while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anticholinergics. | 08-26-2010 |
20110124726 | NOVEL CARBOXYLIC ACID DERIVATIVES - The present invention is concerned with novel arylalkyl carboxylic acid derivatives, more specifically, with acylates of arylalkyl carboxylic acids with naturally occurring, non-toxic hydroxyl, sulfhydryl, amino or imino compounds, and to compositions containing them. The compositions are preferably cosmetic preparations. | 05-26-2011 |
20120035261 | DEUTERIUM-ENRICHED SAXAGLIPTIN - The present application describes deuterium-enriched saxagliptin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 02-09-2012 |
20120225940 | Use of (-) (3-Trihalomethylphenoxy) (4-Halophenyl) Acetic Acid Derivatives for Treatment of Insulin Resistance, Type 2 Diabetes, Hyperlipidemia and Hyperuricemia - The present invention provides the use of (−) (3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia. | 09-06-2012 |
20130150441 | Oligomer-Anticholinergic Agent Conjugates - The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different as compared to the characteristics of the small molecule drug not attached to the water-soluble oligomer. | 06-13-2013 |
20130267593 | METHODS AND COMPOSITIONS FOR ADMINISTRATION OF OXYBUTYNIN - Administration of Oxybutynin directly to a patient's lungs for treating urinary incontinence, respiratory disease or IBD. | 10-10-2013 |
20130274331 | Method for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halofenic Acid and an Anti-Inflammatory Agent - Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a urate-lowering agent and an anti-inflammatory agent. In some aspects the urate-lowering agent is (−)-halofenate, (−)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second agent is an anti-inflammatory agent, or a pharmaceutically acceptable salt thereof. | 10-17-2013 |
20130281531 | POLYMORPHS OF 4-[2-DIMETHYLAMINO-1-(1-HYDROXYCYCLOHEXYL)ETHYL]PHENYL 4-METHYL-BENZOATE HYDROCHLORIDE, METHODS FOR PREPARING THE SAME AND USE OF THE SAME - The present disclosure relates to polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same. | 10-24-2013 |
20140135392 | METHODS FOR THE TREATMENT OF SIALORRHEA - The present invention provides safe and effective methods for the treatment of sialorrhea (excessive drooling) by administering an effective amount of N-desethyloxybutynin, or an optical R- or S-isomer thereof. N-desethyloxybutynin is a metabolite of oxybutynin and has higher affinity for receptors present in the parotid glands (the salivary glands in humans) than oxybutynin. | 05-15-2014 |
20140357713 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE - The present disclosure provides antimicrobial compounds, compositions comprising such antimicrobial compounds, and methods of their use, in particular, antibacterial compounds and antifungal compounds. In certain aspects, the antimicrobial compounds are effective against pathogens of hospital-acquired infections. In certain aspects, the antimicrobial compounds are effective against pathogens that are resistant to antibiotics. The antimicrobial compounds can be used in antibacterial compositions, antifungal compositions, antiseptic compositions and disinfectant compositions. The antimicrobial compounds can be used as adjuncts in antibacterial compositions and antifungal compositions. | 12-04-2014 |
20160031807 | NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX - The disclosed subject matter provides N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure. | 02-04-2016 |
20160122283 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of hyperuricemia, gout, dyslipidemia, obesity, urea cycle disorders, hyperglycemia, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, prediabetes, obesity, arrhythmia, myocardial infarction, stroke, neuropathy, renal complications, hypertriglyceridemia, cardiovascular complications, and post prandial hyperglycemia. | 05-05-2016 |
20160145192 | QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS FOR OPHTHALMIC USE - The present invention relates to nitric oxide donor compounds having a quinone based structure, to processes for their preparation and to their use in the treatment and/or prophylaxis of glaucoma and ocular hypertension. | 05-26-2016 |
20160151321 | METHODS FOR THE TREATMENT OF SIALORRHEA | 06-02-2016 |